RHEACELL

What RHEACELL does

RHEACELL GmbH & Co. KG is a privately held, founder-controlled clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing allogeneic cell therapies based on its proprietary ABCB5+ mesenchymal stromal cell (MSC) platform. The platform exploits a specific subpopulation of MSCs derived from human skin that exhibits immunomodulatory properties — switching macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes via IL-1RA release — enabling both topical and systemic (intravenous) administration for inflammation-driven rare diseases. RHEACELL's exclusive license to the ABCB5 gene and protein patent portfolio (37+ patents) from Boston Children's Hospital and Brigham and Women's Hospital (Harvard Medical School) underpins the technology, supplemented by a proprietary GMP-certified manufacturing process the company controls end-to-end from cell production to batch release.

The company's commercial asset is AMESANAR®, an allogeneic ABCB5+ MSC therapy that received national marketing authorization in Germany in 2021 under § 4b AMG for the topical treatment of non-healing chronic venous ulcers (CVU); it is the second authorized somatic cell therapy product in Germany. As of November 1, 2025, AOP Health assumed the marketing authorization holder role and took over European distribution. The development pipeline targets high-unmet-need orphan indications: pivotal Phase III for Recessive Dystrophic Epidermolysis Bullosa (RDEB, across Europe, US, South America, and Taiwan) and Phase III for therapy-resistant CVU (FDA/EMA approved 2024), with earlier-stage programs in diabetic foot ulcers, polycystic kidney disease, acute graft-versus-host disease, and transplant rejection. The company has secured FDA Orphan Drug Designation, EMA Orphan Drug Designation, FDA RMAT designation (2024), and an EMA-approved Pediatric Investigation Plan for EB.

RHEACELL operates a clinical-development-led, sales-light business model. Revenue is expected to derive from AMESANAR® sales (now distributed through AOP Health in Europe) and, over time, from pipeline assets upon regulatory approval; no public pricing is disclosed. GTM centers on enterprise/clinical partnerships, multinational late-stage trials run through academic medical centers, and patient advocacy engagement (e.g., debra of America). The company employs over 110 staff across two Heidelberg locations and is led by founder-CEO Dr. Christoph Ganss, with no disclosed institutional investors.

Name

RHEACELL

Legal name

RHEACELL GmbH & Co. KG

Website

https://rheacell.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

RHEACELL is a Heidelberg-based clinical-stage biopharmaceutical company developing allogeneic ABCB5+ mesenchymal stromal cell therapies for rare, inflammation-driven diseases, with one approved product (AMESANAR®) in Germany and a Phase III pipeline led by Epidermolysis Bullosa.

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Stem cell therapies
• Cell therapy products
• Biopharmaceutical research
• Mesenchymal stromal cells
• Rare disease treatments

Headquarters

HQ city

Heide

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D

Revenue model

1. AMESANAR® Sales: Sales of AMESANAR®, an approved cell therapy product for chronic venous ulcers (CVU) granted national marketing authorization in Germany in 2021. As of November 2025, AOP Health became the marketing authorization holder and took over distribution.
2. Clinical Development Pipeline: Revenue anticipated from late-stage pipeline products including RDEB treatment, DFU, PKD, and GvHD therapies through clinical trials and eventual market authorization

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

RHEACELL develops and manufactures allogeneic ABCB5+ mesenchymal stromal cell (MSC) therapies for rare and severe inflammation-driven diseases. Its marketed product, AMESANAR®, is a topically applied ABCB5+ MSC therapy approved in Germany since 2021 for chronic venous ulcers, and its late-stage pipeline targets Recessive Dystrophic Epidermolysis Bullosa (RDEB) in pivotal Phase III trials, with additional programs in diabetic foot ulcers, polycystic kidney disease, acute GvHD, and transplant rejection.

Product overview

RHEACELL is a fully integrated biopharmaceutical company focused on developing innovative stem cell therapies based on its proprietary ABCB5+ mesenchymal stromal cells (MSCs) platform technology. The company's marketed product is AMESANAR®, a cell therapy for chronic venous ulcers (approved in Germany in 2021). The development pipeline includes ABCB5+ MSC therapies for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in pivotal Phase III trials (Europe, US, South America, Taiwan), chronic venous ulcers in Phase III, diabetic foot ulcers in Phase I/IIa, polycystic kidney disease, acute GvHD, and transplant rejection. The ABCB5+ platform technology enables targeting of inflammation to facilitate tissue recovery and wound healing across multiple rare and orphan diseases.

Differentiator

Problem solved

Functional benefit

Brands

• AMESANAR: Cell therapy product for chronic venous ulcers (CVU) with national marketing authorization in Germany. Contains ABCB5+ mesenchymal stromal cells for topical application.

Products and services

• AMESANAR® AMESANAR® is an allogeneic ABCB5+ mesenchymal stromal cell therapy approved in Germany for topical treatment of patients with non-healing chronic venous ulcers (CVU); distributed in Europe by AOP Health since November 1, 2025.

Quantifiable outcome

• Phase IIa trial in 16 RDEB patients demonstrated significant reduction in wound number and severity, plus significant reduction in itch and pain
• +1 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• AOP HealthcoreChannel Partner/ Reseller/ Distributor · 1 May 2025Strategic partnership formed in May 2025 for commercialization of novel somatic cell therapies in Europe. AOP Health became the marketing authorization holder and took over distribution of AMESANAR® as of November 1, 2025. The partnership aims to deliver breakthrough therapies for 'butterfly children's disease' (EB) and chronic venous wounds.
• The Whiteley ClinicsupportingStrategic or Co-development Partner · 1 November 2024UK-based clinic serving as Principal Investigator site for Phase III study on therapy-resistant chronic venous ulcers. Dr. Mark Whiteley serves as Principal Investigator.
• EB-Haus SalzburgsupportingStrategic or Co-development Partner · 1 June 2023Austria-based specialized EB treatment center that started the pivotal Phase III study for severe forms of Epidermolysis bullosa as 'First Patient In' site.
• FGK Clinical Research GmbHsupportingImplementation/ SI/ Consulting Partner · 1 January 2023Clinical research organization providing support for the Phase III study on therapy-resistant chronic venous ulcers, particularly for the UK study center activation.
• Ulm University Medical CentersupportingStrategic or Co-development Partner · 1 January 2022Collaboration recognized with Kooperationspreis Wissenschaft-Wirtschaft 2022. Prof. Dr. med. Karin Scharffetter-Kochanek serves on RHEACELL's Scientific Advisory Board.
• Boston Children's Hospital and Brigham and Women's Hospital (Harvard Medical School)coreTechnology or Integration · 1 January 2003Exclusive license to the full ABCB5 gene and protein patent portfolio (37+ exclusive patents) from Boston Children's Hospital and Brigham and Women's Hospital, Harvard Medical School. Several patents are co-owned by RHEACELL. This IP protection forms a cornerstone of the company's competitive advantage.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Mesoblast: Clinical-stage biopharma developing allogeneic mesenchymal stromal cell therapies for inflammatory and immune-mediated diseases. Highly comparable platform technology (off-the-shelf MSC) targeting similar mechanisms (anti-inflammatory, immunomodulatory) in rare and chronic indications.
• Holostem Terapie Avanzate: Italian biotech developing autologous and allogeneic epithelial stem cell therapies for rare eye and skin diseases including limbal stem cell deficiency (LSCD) — a direct overlap with RHEACELL's ABCB5+ MSC program for LSCD and EB-related ocular surface disease.
• Abeona Therapeutics: U.S. biotech developing cell and gene therapies for recessive dystrophic epidermolysis bullosa (RDEB), including the autologous gene-modified cell therapy EB-101. Directly competes with RHEACELL's allogeneic ABCB5+ MSC approach in the same lead indication.
• Athersys / Healios: Developers of MultiStem, an allogeneic bone marrow-derived MSC therapy for inflammatory and immune-mediated indications including GvHD and ischemic conditions. Directly comparable allogeneic cell therapy platform targeting similar indications in RHEACELL's pipeline.
• Capricor Therapeutics: Clinical-stage biotech developing cell-derived exosome and cell therapy products for rare diseases, including Duchenne muscular dystrophy. Comparable late-stage cell therapy developer with regulatory designations (Orphan, RMAT) and orphan-indication strategy.
• Castle Creek Biosciences: Clinical-stage cell and gene therapy company focused on rare skin and connective tissue disorders, including EB. Comparable in deploying cell-based modalities for orphan dermatological indications with high unmet need.
• Pluristem Therapeutics: Cell therapy company developing placenta-derived allogeneic MSC-like products for inflammatory and ischemic conditions. Comparable off-the-shelf cell therapy platform with similar anti-inflammatory mechanism and orphan-indication focus.

Emerging players

• Pharmicell: South Korea-based cell therapy company with an approved autologous MSC product (Cartistem) and pipeline in inflammatory and rare diseases. Comparable allogeneic/autologous MSC development with similar regulatory pathway learnings.

Broad incumbents

• TiGenix (Takeda): Takeda acquired TiGenix for Cx601 (darvadstrocel), an allogeneic adipose-derived MSC therapy approved in Europe for complex perianal fistulas in Crohn's disease. Highly comparable allogeneic MSC regulatory and commercial pathway relevant to RHEACELL's GvHD and inflammation pipeline.

Others

• AOP Health: European specialty pharma commercializing rare disease and critical care therapies; RHEACELL's strategic partner and current marketing authorization holder for AMESANAR®. Closely tied to RHEACELL's commercial pathway but not a product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInde.linkedin.com/company/rheacell
• Instagraminstagram.com/rheacellgmbh

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RHEACELL